重要文件

檢視所有文件

跳轉至

1161586

USP

L -胱氨酸

Name: <SC>L </SC>-胱氨酸
Brand: USP

United States Pharmacopeia (USP) Reference Standard

同義詞:

(R,R)-3,3′-亚二硫基二(2-丙氨酸)

登入檢視組織與合約價格。

選擇尺寸

變更視圖

包裝尺寸	庫存單位	供貨能力	價格

關於此項目

線性公式:

[-SCH₂CH(NH₂)CO₂H]₂

CAS 編號:

56-89-3

分子量：:

240.30

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329749499

MDL number:

MFCD00064228

Beilstein/REAXYS Number:

1728094

暫時無法取得訂價和供貨情況

技術服務

需要援助？我們經驗豐富的科學家團隊隨時樂意為您提供支援。

讓我們為您提供幫助

屬性

grade

pharmaceutical primary standard

API family

cystine

manufacturer/tradename

USP

mp

>240 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O

InChI

1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1

InChI key

LEVWYRKDKASIDU-IMJSIDKUSA-N

描述

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cystine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

比較類似項目

查看完整比較

Show Differences

1 of 1

本產品	C3300000	C5735	49603
USP 1161586 Cystine	C3300000 Cystine	SAFC C5735 L-Cystine	Supelco 49603 L-Cystine
manufacturer/tradename USP	manufacturer/tradename EDQM	manufacturer/tradename -	manufacturer/tradename Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade -	grade certified reference material, TraceCERT^®
format neat	format neat	format -	format neat
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) cleaning products cosmetics flavors and fragrances food and beverages personal care
storage temp. 2-8°C	storage temp. -	storage temp. -	storage temp. -
mp >240 °C (dec.) (lit.)	mp >240 °C (dec.) (lit.)	mp >240 °C (dec.) (lit.)	mp >240 °C (dec.) (lit.)

Still not finding the right product?

Explore all of our products under L -胱氨酸

存儲類別/等級

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Propensity for biofilm formation by clinical isolates from urinary tract infections: developing a multifactorial predictive model to improve antibiotherapy.

Maria José Alves et al.

Journal of medical microbiology, 63(Pt 3), 471-477 (2014-01-17)

A group of biofilm-producing bacteria isolated from patients with urinary tract infections was evaluated, identifying the main factors contributing to biofilm formation. Among the 156 isolates, 58 (37.2%) were biofilm producers. The bacterial species (P<0.001), together with patient's gender (P

Comparison of FecalSwab and ESwab devices for storage and transportation of Diarrheagenic bacteria.

Jari J Hirvonen et al.

Journal of clinical microbiology, 52(7), 2334-2339 (2014-04-18)

Using a collection (n = 12) of ATCC and known stock isolates, as well as 328 clinical stool specimens, we evaluated the ESwab and the new FecalSwab liquid-based microbiology (LBM) devices for storing and transporting diarrheagenic bacteria. The stock isolates

Common mutation causes cystinosis in the majority of black South African patients.

E Patricia Owen et al.

Pediatric nephrology (Berlin, Germany), 30(4), 595-601 (2014-10-19)

The mutations responsible for cystinosis in South African patients are currently unknown. A pertinent question is whether they are similar to those described elsewhere in the world. Children who were being managed for cystinosis in the Western Cape Province of